Three IPOs currently open for subscription are Fusion CX Limited, Sahajanand Medical Technologies Limited, and Ravita Engineering Services Limited. The issues cover global BPO/KPO customer experience solutions, advanced vascular medical devices, and specialized electromechanical engineering services.
The details below cover each issue, including timeline, price band, lot size, financials and stated use of proceeds.
Fusion CX Limited

Fusion CX Limited is a global provider of Business Process Outsourcing (BPO) and Knowledge Process Outsourcing (KPO) solutions. The company offers customer experience management, multilingual technical support, and digital transformation services. It serves enterprise clients across North America, Europe, and Asia-Pacific, incorporating proprietary AI platforms (such as Arya and MindVoice) into its service operations.
| IPO dates | October 14, 2026 to October 16, 2026 |
| Price band | ₹275 to ₹289 per equity share |
| Lot size | 51 shares |
| Issue size | Approx. ₹702 crore, including a fresh issue of ₹500 crore and an Offer for Sale of ₹202 crore |
| Minimum investment | ₹14,739 at the upper price band |
Total rotal revenue moved from ₹1,021.53 crore in FY24 to ₹1,851.83 crore in FY26, and reached ₹503.85 crore in Q1 FY27. Profit after tax was ₹169.84 crore in FY26, compared with ₹36.26 crore in FY24, and stood at ₹55.70 crore for Q1 FY27. EBITDA grew from ₹104.62 crore in FY24 to ₹329.87 crore in FY26.
The company has stated that ₹275.70 crore of net proceeds will be used for repayment or prepayment of certain borrowings of the company and its subsidiaries. Additionally, ₹61.15 crore will be allocated toward IT infrastructure and upgrading proprietary AI platforms, with the balance planned for general corporate purposes and strategic acquisitions.
Sahajanand Medical Technologies Limited

Sahajanand Medical Technologies (SMT) Limited is a medical device company focused on the design, development, manufacturing, and commercialization of vascular medical devices. Its core portfolio includes Drug-Eluting Stents (DES), renal stenting solutions, and balloon catheters. SMT holds a market share of nearly 25% in India's DES market and distributes products across 77 countries, operating manufacturing plants in Surat, Hyderabad, and Thailand.
| IPO dates | October 15, 2026 to October 19, 2026 |
| Lot size | 1,600 shares |
| Price Band | ₹327 to ₹344 per equity share |
| Issue size | Approx. ₹475.48 crore, entirely an Offer for Sale of 1.38 crore equity shares |
| Minimum retail application | 43 shares |
Revenue from operations moved from ₹587.84 crore in FY24 to ₹894.20 crore in FY26. Research & Development expenses were maintained at 8.61% of operational revenue in FY26 compared with 9.04% in FY24. PAT margin for Q1 FY27 stood at 4.29%, while Net Asset Value (NAV) per share was ₹64.35 as of June 30, 2026.
As the IPO is entirely an Offer for Sale (OFS), all proceeds will go to the selling shareholders, and the company will not receive any funds from the issue
Ravita Engineering Services Limited

Ravita Engineering Services Limited provides Engineering, Procurement, Installation, and Commissioning (EPIC) alongside Operations and Maintenance (O&M) services for electromechanical, HVAC, and utility systems. The company specializes in technical operations across complex environments, including offshore oil & gas rigs, marine platforms, and data centers. As of June 30, 2026, its unexecuted order book stood at ₹491.12 crore.
| IPO dates | October 14, 2026 to October 16, 2026 |
| Price band | ₹105 to ₹112 per equity share |
| Issue size | ₹116.05 crore, entirely a fresh issue |
| Minimum retail application | 1,200 Equity Shares (Minimum retail application: 2 lots, or 2,400 shares, amounting to ₹2,52,000) |
Revenue from operations grew from ₹13.49 crore in FY24 to ₹277.63 crore in FY26. Profit after tax rose to ₹28.04 crore in FY26, compared with ₹1.51 crore in FY24. The company's EBITDA margin stood at 14.42% for Q1 FY27, while its order book expanded from ₹83.87 crore in FY25 to ₹491.12 crore by Q1 FY27.
The company plans to use ₹70.00 crore of net proceeds to meet long-term working capital requirements and ₹25.53 crore for capital expenditure toward the purchase of heavy equipment and machinery. The remaining proceeds are marked for general corporate operational expenses.
Disclaimer: This article is for informational purposes only and should not be considered investment advice. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions.






.png)
.png)
